AAAAAA

   
Results: 1-9 |
Results: 9
INDIVIDUALIZING THERAPY TO PREVENT POSTMENOPAUSAL OSTEOPOROSIS - A COMPARISON OF HORMONE-THERAPY, ALENDRONATE, AND RALOXIFENE
Authors: COL NF PAUKER SG GOLDBERG RJ ECKMAN MH ORR RK ROSS EM WONG JB
Citation: Nf. Col et al., INDIVIDUALIZING THERAPY TO PREVENT POSTMENOPAUSAL OSTEOPOROSIS - A COMPARISON OF HORMONE-THERAPY, ALENDRONATE, AND RALOXIFENE, Medical decision making, 18(4), 1998, pp. 467-467
THE LEARNING-CURVE FOR SENTINEL NODE BIOPSY IN BREAST-CANCER - PRACTICAL CONSIDERATIONS WHEN INTRODUCING NEW TECHNOLOGY
Authors: ORR RK COL NF HOEHN JL
Citation: Rk. Orr et al., THE LEARNING-CURVE FOR SENTINEL NODE BIOPSY IN BREAST-CANCER - PRACTICAL CONSIDERATIONS WHEN INTRODUCING NEW TECHNOLOGY, Medical decision making, 18(4), 1998, pp. 478-478
IMPACT OF POSTMENOPAUSAL HORMONE-THERAPY ON CARDIOVASCULAR EVENTS ANDCANCER - STUDYS CONCLUSIONS WERE INCORRECT
Authors: COL NF WONG JB PAUKER SG KARAS R
Citation: Nf. Col et al., IMPACT OF POSTMENOPAUSAL HORMONE-THERAPY ON CARDIOVASCULAR EVENTS ANDCANCER - STUDYS CONCLUSIONS WERE INCORRECT, BMJ. British medical journal, 315(7109), 1997, pp. 678-678
FACILITATING PATIENT-SPECIFIC DECISIONS REGARDING HORMONE REPLACEMENTTHERAPY - REPLY
Authors: COL NF PAUKER SG ECKMAN MH WONG JB
Citation: Nf. Col et al., FACILITATING PATIENT-SPECIFIC DECISIONS REGARDING HORMONE REPLACEMENTTHERAPY - REPLY, JAMA, the journal of the American Medical Association, 278(6), 1997, pp. 476-476
PATIENT-SPECIFIC DECISIONS ABOUT HORMONE REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN
Authors: COL NF ECKMAN MH KARAS RH PAUKER SG GOLDBERG RJ ROSS EM ORR RK WONG JB
Citation: Nf. Col et al., PATIENT-SPECIFIC DECISIONS ABOUT HORMONE REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN, JAMA, the journal of the American Medical Association, 277(14), 1997, pp. 1140-1147
SHOULD THE NORMAL 25-HYDROXY VITAMIN-D LEVEL BE INCREASED
Authors: ROSS EM ROSENBERG IH DAWSONHUGHES B COL NF WONG JB
Citation: Em. Ross et al., SHOULD THE NORMAL 25-HYDROXY VITAMIN-D LEVEL BE INCREASED, The American journal of clinical nutrition, 66(1), 1997, pp. 18-18
THE IMPACT OF CLINICAL-TRIALS ON THE USE OF MEDICATIONS FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF A COMMUNITY-BASED STUDY
Authors: COL NF MCLAUGHLIN TJ SOUMERAI SB HOSMER DW YARZEBSKI J GURWITZ JH GORE JM GOLDBERG RJ
Citation: Nf. Col et al., THE IMPACT OF CLINICAL-TRIALS ON THE USE OF MEDICATIONS FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF A COMMUNITY-BASED STUDY, Archives of internal medicine, 156(1), 1996, pp. 54-60
DOES ASPIRIN CONSUMPTION AFFECT THE PRESENTATION OR SEVERITY OF ACUTEMYOCARDIAL-INFARCTION
Authors: COL NF YARZEBSKI J GORE JM ALPERT JS GOLDBERG RJ
Citation: Nf. Col et al., DOES ASPIRIN CONSUMPTION AFFECT THE PRESENTATION OR SEVERITY OF ACUTEMYOCARDIAL-INFARCTION, Archives of internal medicine, 155(13), 1995, pp. 1386-1389
FREQUENCY OF INCLUSION OF PATIENTS WITH CARDIOGENIC-SHOCK IN TRIALS OF THROMBOLYTIC THERAPY
Authors: COL NF GURWITZ JH ALPERT JS GOLDBERG RJ
Citation: Nf. Col et al., FREQUENCY OF INCLUSION OF PATIENTS WITH CARDIOGENIC-SHOCK IN TRIALS OF THROMBOLYTIC THERAPY, The American journal of cardiology, 73(2), 1994, pp. 149-157
Risultati: 1-9 |